Trial Profile
A Randomized Open-Label, Phase 1b Study of the Safety of Pirfenidone Solution for Inhalation (AP01) in Patients with Idiopathic Pulmonary Fibrosis (ATLAS Study)
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 17 Nov 2023
Price :
$35
*
At a glance
- Drugs Pirfenidone (Primary) ; Salbutamol
- Indications Idiopathic pulmonary fibrosis
- Focus Adverse reactions
- Acronyms ATLAS
- Sponsors Avalyn Pharma
- 09 Nov 2023 According to Avalyn Pharma media release, data from this study presented at 2023 Pulmonary Fibrosis Foundation (PFF) Summit
- 09 Nov 2023 Results published in the Avalyn Pharma Media Release
- 12 Sep 2023 Results of meta analysis to compare FVC findings from the IPF patients enrolled in ATLAS to four studies (ASCEND, NPULSIS-1, INPULSIS-2 and INBUILD) presented in the Avalyn Pharma Media Release